Wellnex Life Limited (Wellnex, WNX or Company) (ASX:WNX), owner and developer of some of Australia's leading health brands, has recently published a key ASX announcement. 

Expansion into the United Kingdom: Wellnex Life receives its opening purchase order from Haleon for the Paracetamol Soft Gel Liquid Analgesic for the United Kingdom

Announcement Highlights

• Wellnex Life receives first Purchase Order for TGA registered paracetamol soft gel liquid analgesic for the UK market
  
  
• The expansion into the UK market builds on the launch of the Australian market which commenced in FY23 and the imminent launch into the United Arab Emirates
  
  
• Wellnex Life is proud to supply one of the world’s largest independent consumer healthcare companies Haleon with this innovative product for use in one of the world’s most trusted pain relief brands - Panadol
  
  
• The arrangement with Haleon is a testament and validation of Wellnex’s business model of being the owner of healthcare brands and IP for the Australian and global markets
  
  

Wellnex Life Limited (ASX: WNX) is pleased to announce that Haleon has submitted the first Purchase Order (PO) for the Paracetamol Soft Gel Liquid Analgesic for the UK market.

Wellnex Life, as announced on 29 June 2023, agreed to extend the supply agreement with Haleon by increasing the product offerings and territories to take advantage of the unique and innovative TGA approved products. This builds on the successful launch in Australia where Wellnex Life has been supplying product to Haleon for one of the worlds most trusted pain relief brands - Panadol.

Haleon is a world-leading consumer healthcare company that owns brands including Panadol, Sensodyne, Voltaren, Polident, Centrum, Otrivin and Advil. 

This significant step in the launch of an important market in the UK and working with one of world’s largest consumer healthcare companies highlights the benefits of Wellnex’s business model of identifying innovative healthcare products enabling Wellnex to secure valuable agreements with leading partners, such as Haleon.

"The launch with Haleon for the UK market for our TGA registered paracetamol soft gel liquid analgesic for one of Europe’s largest markets is an important milestone for the Company. The trust and confidence imparted upon Wellnex to supply one of the world’s leading pain relief brands in Panadol is a validation and testament to our Wellnex Life’s business model."

Read the full Announcement here.

To learn more about Wellnex Life and stay up to date with investor information, subscribe to the Company's Chairman’s List.